Have you ever told your child to do something right one time, and then they did it correctly forever? If you are like most of us, that never happens. Yet this week CMS announced that they were applying this concept to diabetes education for Medicare age patients with an A1c of …
Read More »Daily Archives: Nov 11, 2017
Vitamin D’s Role In Preventing Type 1 Diabetes
Vitamin D supplementation could possibly reduce the risk of type 1 diabetes in susceptible children.
Read More »Reduced Sugar Claims Misleading
New study suggests packaged food claims like “reduced in sugar” or “no added sugar” still have sugar levels too high by World Health Organization standards.
Read More »Degludec Compared with Glargine in Study
New insulin formulation emerges as safe alternative to long-acting insulins and inconsistent glycemic levels, but could have higher risk of cardiovascular events.
Read More »Stopping Antiplatelet Therapy and Its Incidence of Cardiovascular Events
Patients who discontinue their daily aspirin for heart disease prevention may be at risk of further complications.
Read More »Bedroom Television Associated with Childhood Adiposity
Screen-based media in a child's room found to have an independent risk factor for overweight and increased body fatness.
Read More »Health Benefits
Which do you feel plays a more important role in the health of your patients with diabetes? 1) Nutrition 2) Exercise 3) Both
Read More »Achieving A1C Target
Your patient has been taking metformin, glipizide, and a daily basal insulin dose (.85 U/kg/day). While his fasting glucose levels are on target, he has not yet been able to reach his individualized glycemic target of A1C<7%. In your discussion with him about the addition of a prandial insulin dose to his regimen, you compare and contrast his options. Compared to basal insulin alone, premixed insulins: A. tend to lower A1c to a larger degree. B. are associated with less weight gain. C. cause less hypoglycemia. D. are a good option for people with irregular meal schedules. Follow the link to see the right answer.
Read More »Samuel Engel Current Interview
Dr. Sam Engel is the Associate Vice President, Cardiometabolic and Women’s Health at Merck Research Laboratories. He graduated from New York University School of Medicine. Prior to joining Merck’s team, he was a Clinical Professor at Albert Einstein College of Medicine.
Read More »Samuel Engel Transcript
Samuel Engel discusses Merck's VERTIS clinical trial program and recent ertugliflozin research including the VERTIS SITA study and the VERTIS MET study,
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.